Real-world outcomes of advanced melanoma patients not represented in phase 3 trials
?Source: MDLinx, June 2020
Researchers sought to report on systemically treated patients with advanced melanoma, that were not represented in phase 3 trials, to support clinical decision-making. Advanced melanoma patients diagnosed between 2014 and 2017 in the Netherlands, treated with immune- or targeted therapy, who met ≥ 1 trial exclusion criteria were included in this analysis. Derivation of the criteria was done from the KEYNOTE-006 and CHECKMATE-067/-066 phase 3 trials.
